TriSalus Life Sciences, Inc.
NasdaqGM TLSI
TriSalus Life Sciences, Inc. Market Capitalization on January 14, 2025: USD 143.01 M
-
TriSalus Life Sciences, Inc. 52-week high Market Capitalization is USD 281.91 M on April 01, 2024, which is 97.13% above the current Market Capitalization.
-
TriSalus Life Sciences, Inc. 52-week low Market Capitalization is USD 109.19 M on October 31, 2024, which is -23.65% below the current Market Capitalization.
-
TriSalus Life Sciences, Inc. average Market Capitalization for the last 52 weeks is USD 183.89 M.
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
| CEO | Ms. Mary T. Szela B.S.N., M.B.A. |
| IPO Date | Feb. 8, 2021 |
| Location | United States |
| Headquarters | 6272 West 91st Avenue |
| Employees | 107 |
| Sector | Health Care |
| Industries | |
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email